Insider buying last 90 days
No open-market insider purchases were filed for RGC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every RGC insider filing, plotted on the chart in Gekko.Open RGC in Gekko
NASDAQ: RGC
Regencell Bioscience (RGC) Stock Analysis & Forecast
Oct 12 close
$7.13−0.22 (−3.0%)
Gekko Brief
AI summaryOct 12 closeRegencell this week drew fresh scrutiny after reporting a wider full-year net loss of $11.7 million, or $2.37 per share, for the period ending June 30, 2026, up from $3.58 million a year earlier, with no product sales revenue generated. The company also released its Annual Report on Form 20-F detailing the loss alongside increased general and administrative expenses. Coverage has focused on whether the company's valuation, including a cited price-to-book ratio of 2,889x, can be justified given the absence of revenue and ongoing losses.
Shares closed at $7.13, down 3% on the day, sitting between the 50-day average of $5.98 and the 200-day average of $18.78. The stock has returned 26.4% over one month and 26.2% over three months, but is down 77.9% over six months and 61.3% over one year, with a typical daily move of 7.3%. The GekkoIndex reads 50.6, placing it in the Neutral zone, while the price sits 19.6% above the Gekko Fair Value of $5.96.
The next earnings date falls on 28 October 2026, 16 days away and inside a typical 20-trading-day holding window, with the last reaction at 3.1% and an average absolute reaction of 9.4% across the last four quarters. Seasonality from this point in the calendar has averaged -3.9% over the next 20 trading days across 5 years, rising in 3 of them. No insider, Congress or unusual options activity appears in the current window.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Regencell Bioscience price vs fair value
Close $7.13200-day averageGekko Fair Value $5.96
Regencell Bioscience quick facts
- Market cap
- $3.53B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.02
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.17
- Volume
- 129,936 avg 137,419
- 1-year return
- −61.3%
- Typical daily move
- ±7.3%
- Typical 20-day move
- ±19.6%
- 50-day average
- $5.98
- 200-day average
- $18.78
- Next earnings
- Oct 28
- Shares outstanding
- 494.5M
Regencell Bioscience swing-trade checklist
Regencell Bioscience scores 0 supportive, 3 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
0 supportive3 mixed2 headwinds
- Trendmixed
Averages disagree
Close $7.13 sits between the 50-day ($5.98) and 200-day ($18.78) averages, or the averages disagree.
See the chart - GekkoIndexmixed
50.6, Neutral
Reading 50.6 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
19.6% above
Price is 19.6% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 16 days
Reports on Oct 28, 2026, 16 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−3.9% on average
From this point in the calendar, the next 20 trading days averaged −3.9% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Regencell Bioscience stock chart and price history
Regencell Bioscience closed at $7.13 on Oct 12, 2026, −61.3% over the past year, inside a 52-week range of $4.51 to $69.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +26.4%
- 3 months
- +26.2%
- 6 months
- −77.9%
- 1 year
- −61.3%
The full RGC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RGC in Gekko
Follow Regencell Bioscience through every session
Put RGC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track RGC in GekkoFree for 7 days. No credit card required.
About Regencell Bioscience
Regencell Bioscience works within Traditional Chinese Medicine, directing its efforts toward treatments for neurocognitive conditions and related forms of degeneration. Its research and development work centers on bringing TCM-based solutions to market, with particular attention paid to attention deficit hyperactivity disorder and autism spectrum disorder. This focus on neurocognitive health built around traditional medicine practices defines its presence in the space.
The company's work spans the full process of developing these treatments, from early research through to eventual market introduction, suggesting an operation built around translating TCM approaches into usable therapeutic solutions for the conditions it targets.
Regencell Bioscience was established in 2014 and is headquartered in Causeway Bay, Hong Kong. Its shares trade on the NASDAQ under the ticker RGC.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- regencellbioscience.com
Regencell Bioscience GekkoIndex: the smart money zone
Regencell Bioscience’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.6, in the Neutral zone, up 7.2 points over five sessions.
50.6Neutral
Up 7.2 points over five sessions, from the Distribution zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 47 | −10.6% | −16.5% | ||
| Accumulation | 130 | +0.3% | +5.2% | ||
| Neutral (current zone) | 134 | +3.5% | −0.1% | ||
| Distribution | 14 | −10.3% | +14.9% | ||
| Selling | 2 | Too few readings yet | |||
Average RGC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the RGC price, zone by zone.Track RGC in Gekko
Is Regencell Bioscience stock overvalued? Gekko Fair Value
Regencell Bioscience trades 19.6% above Gekko Fair Value of $5.96, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Regencell Bioscience shares are worth, recalculated every trading day.
$5.96
Gekko Fair Value, Oct 10, 2026
19.6% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open RGC in Gekko
Regencell Bioscience insider and Congress trading
No open-market insider purchases were filed for Regencell Bioscience, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in RGC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for RGC, plotted on the chart in Gekko.Open RGC in Gekko
Buybacks
Regencell Bioscience has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.78M
- As a share of market cap
- 0.05%
From company filings.
Regencell Bioscience earnings: next date and track record
Regencell Bioscience reports on Oct 28, 2026 (16 days away), and beat the EPS estimate in 0 of its last 4 reports.
Next earnings report
Oct 28, 2026
16 days away
0 of 4reports beat the EPS estimate
±9.4%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 24, 2025 | $0.00 est $0.00 | — | +3.1% |
| Jun 26, 2025 | −$0.14 | — | −19.9% |
| Oct 25, 2024 | $0.00 est $0.00 | — | +33.2% |
| Jan 26, 2024 | $0.00 | — | −1.2% |
| Oct 27, 2023 | −$0.01 | — | −7.9% |
| Jan 30, 2023 | −$0.01 | — | −0.3% |
| Oct 31, 2022 | −$0.30 est $0.00 | — | −3.7% |
| Jun 2, 2022 | −$0.29 est $0.00 | — | +5.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Regencell Bioscience seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Regencell Bioscience averaged −3.9% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.3% | 3 of 5 |
| Next 10 trading days | −12.4% | 1 of 5 |
| Next 15 trading days | −1.9% | 2 of 5 |
| Next 20 trading days | −3.9% | 3 of 5 |
| Next 30 trading days | −9.9% | 2 of 5 |
For scale, RGC’s typical 20-trading-day move in either direction is about 19.6%.
Regencell Bioscience market cap and key statistics
Regencell Bioscience’s market cap is $3.53B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $3.53B
- EPS, TTM
- −$0.02
- Gekko Fair Value
- $5.96
Trading
- Volume
- 129,936
- Avg volume, 20 days
- 137,419
- 52-week high
- $69.00
- 52-week low
- $4.51
- Shares outstanding
- 494.5M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -128.5%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.17
- Typical daily move
- ±7.3%
- Typical 20-day move
- ±19.6%
Regencell Bioscience stock news this week
Coverage of Regencell Bioscience this week reads negative: 0 positive, 0 neutral and 4 negative headlines.
- Regencell Stock Faces Fresh Questions After Wider Full Year LossSimply Wall Street, Oct 10
- Can Regencell Bioscience Holdings (RGC) Justify Its Valuation On A Wider Full Year Loss?Simply Wall Street, Oct 8
- Regencell Bioscience (NASDAQ:RGC) Releases Earnings ResultsDefense World, Oct 8
- With no product sales revenue, Regencell (RGC) posts a wider annual loss.Stock Titan, Oct 7
- Regencell Bioscience : Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)www.marketscreener.com, Oct 7
Regencell Bioscience peers
Regencell Bioscience’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Regencell Bioscience stock FAQ
What is Regencell Bioscience’s market cap?
Regencell Bioscience’s market cap is $3.53B at the Oct 12, 2026 close of $7.13, with 494.5M shares outstanding.
Is Regencell Bioscience stock overvalued or undervalued?
On Gekko’s estimate Regencell Bioscience is overvalued: the Oct 12, 2026 close of $7.13 is 19.6% above Gekko Fair Value of $5.96. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Regencell Bioscience report earnings next?
Regencell Bioscience is expected to report on Oct 28, 2026 (16 days away). Regencell Bioscience beat the earnings estimate in 0 of its last 4 reports, moving 9.4% on average across the report.
What is Regencell Bioscience’s 52-week high and low?
Regencell Bioscience’s 52-week high is $69.00 and its 52-week low is $4.51; it closed at $7.13 on Oct 12, 2026, −61.3% over the past year. Over the last five years the shares peaked at $83.60 on Jun 16, 2025.
Is Regencell Bioscience stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 0 of the 5 items with data read as supportive, 3 as mixed (trend, gekkoindex and seasonality) and 2 as headwinds (fair value and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Regencell Bioscience the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.